What is the impact factor of Annals of Oncology?

Annals of Oncology has an impact factor of 65.4 (2024). This places it among the top-tier journals in its field with Annals of Oncology published by ESMO is a premier international oncology journal.

How long does Ann. Oncol. take to review?

Annals of Oncology typically takes ~90-120 days median. The full review process involves 5 main stages: manuscript preparation, submission via esmo system, and peer review.

All Journal Guides

Journal Guide

Annals of Oncology Impact Factor 65.4: Publishing Guide

Q: What is the acceptance rate of Annals of Oncology?

Annals of Oncology has an acceptance rate of ~10-20%. A common reason for rejection is phase 1/2 trial without mature efficacy data. AO expects mature, significant clinical data. Early-phase work without clear efficacy signal or mechanism insufficient.

Q: Is Annals of Oncology peer reviewed?

Yes, Annals of Oncology is fully peer reviewed. All submissions undergo rigorous peer review by 2-3 leading oncologists assess trial design rigor, outcome significance, mechanistic insight, biomarker validity, and global applicability. First decision 90-120 days..

Oncology: clinical trials, cancer biology, and therapeutic innovation

65.4

Impact Factor (2024)

~10-20%

Acceptance Rate

~90-120 days median

Time to First Decision

What Ann. Oncol. Publishes

Annals of Oncology published by ESMO is a premier international oncology journal. With JIF 65.4 and Q1 ranking in Oncology, AO emphasizes high-impact cancer research combining clinical findings with mechanistic insight. The journal publishes research on cancer treatment, biomarkers, and clinical outcomes. Critically: AO is highly selective, valuing work advancing cancer treatment globally. Routine studies lack competitiveness. The journal seeks papers making major oncology contributions.

Clinical trial outcomes: treatment efficacy, safety, response prediction
Cancer immunotherapy: checkpoint inhibitors, cellular therapy, immune mechanisms
Precision oncology: genomic testing, biomarkers, treatment selection
Solid tumors: lung, breast, colorectal, ovarian, gastric cancers
Hematologic malignancies: leukemia, lymphoma, myeloma
Novel therapies: antibody-drug conjugates, CAR-T, targeted therapies
Resistance mechanisms: drug resistance, combination strategies, overcoming resistance
Cancer biology: tumor microenvironment, immune infiltration, disease mechanisms

Editor Insight

“Annals of Oncology publishes high-impact cancer research advancing global oncology practice. We seek mature clinical trials with significant efficacy and mechanistic insight.”

What Ann. Oncol. Editors Look For

High-impact clinical finding advancing cancer treatment outcomes

Present trial or finding improving cancer patient survival or outcomes. New treatment benefit? Superior biomarker? Prevention strategy? Major clinical impact required.

Rigorous trial design with adequate patient numbers and follow-up

Randomized clinical trials or large translational studies. Sufficient power and mature follow-up for clinical endpoints.

Mechanistic understanding of treatment response or resistance

Explain why therapy works or why resistance emerges. Molecular mechanisms driving clinical outcomes.

Biomarker validation predicting treatment response

Biomarkers validated in independent cohorts enabling patient stratification and treatment selection.

Global applicability and real-world relevance

Show treatment feasible and effective across healthcare systems. Address practical implementation.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Ann. Oncol.'s editorial review:

Phase 1/2 trial without mature efficacy data

AO expects mature, significant clinical data. Early-phase work without clear efficacy signal or mechanism insufficient.

Single-center study without multi-center validation

Single-site findings need independent validation. Multi-center trials strengthen credibility.

No mechanistic explanation of treatment effect

Explain treatment mechanisms. What drives response? What predicts resistance?

Biomarker claims without independent validation

Biomarkers must validate in independent cohorts. Single-cohort discovery insufficient.

Ignoring global context and healthcare disparities

Show treatment applicable globally. Address cost and accessibility issues.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Ann. Oncol.'s criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Ann. Oncol. Authors

Randomized phase 3 trials with survival endpoints most competitive

Mature, powered trials showing overall survival or progression-free survival benefit have highest impact.

Immunotherapy combination and sequencing increasingly valued

Optimizing checkpoint inhibitor combinations and treatment sequences increasingly important.

Predictive biomarkers for treatment selection competitive

Biomarkers enabling precise treatment selection have immediate clinical utility.

Resistance mechanisms and overcoming resistance valued

Understanding and overcoming therapeutic resistance increasingly important as field matures.

Patient-reported outcomes and quality of life emphasized

Patient-centered outcomes increasingly important in modern oncology trials.

The Ann. Oncol. Submission Process

Manuscript preparation

Prep

6,000-9,000 words with 6-8 figures. Include trial design, patient cohort, treatment description, efficacy/safety outcomes, biomarker analysis, mechanistic discussion.

Submission via ESMO system

Day 0

Submit at https://www.annalsofoncology.org/. Required: manuscript emphasizing clinical significance, figures showing efficacy and biomarker data, cover letter highlighting impact.

Editorial assessment

1-2 weeks

Editor assesses trial significance and oncology impact. Routine studies or early-phase work face rejection. Highly selective desk rejection ~50-60%.

Peer review

90-120 days

2-3 leading oncologists assess trial design rigor, outcome significance, mechanistic insight, biomarker validity, and global applicability. First decision 90-120 days.

Revision and publication

Revision: 2-4 weeks

Revisions often minor if accepted. Publication 2-4 weeks after acceptance.

Ann. Oncol. by the Numbers

2024 Impact Factor	14.3
5-Year Impact Factor	14.9
Acceptance rate	~10-20%
Desk rejection rate	~50-60%
Median first decision	~105 days
Open access option	$4,500 USD
Publisher	ESMO
Founded	1990

Before you submit

Ann. Oncol. accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Ann. Oncol.. ~30 minutes.

Run Free Readiness Scan See a sample report

Article Types

Clinical Trial

6,000-9,000 words

Phase 2-3 cancer trial with efficacy outcomes

Translational Research

6,000-9,000 words

Cancer biology with clinical application

Landmark Ann. Oncol. Papers

Papers that defined fields and changed science:

Checkpoint inhibitor trials (2015+) - immunotherapy revolution
Targeted therapy in advanced cancer (2010s+) - precision oncology
Novel combination therapies (2010s+) - overcoming resistance
Biomarker-driven trial designs (2010s+) - patient stratification

Preparing a Ann. Oncol. Submission?

Get pre-submission feedback from reviewers who've published in Ann. Oncol. and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected

Confidential

Primary Fields

Clinical TrialsImmunotherapyBiomarkersPrecision OncologyTreatment Resistance

Related Journal Guides

All journal guides

All articles

Ready to submit to Ann. Oncol.?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Ann. Oncol. editors look for.

Need field-expert depth? Human review from $1,000